Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib

被引：91
作者：
Gardini, Andrea Casadei [1 ]
Scarpi, Emanuela [2 ]
Faloppi, Luca [3 ,4 ]
Scartozzi, Mario [4 ]
Silvestris, Nicola [5 ]
Santini, Daniele [6 ]
de Stefano, Giorgio [7 ]
Marisi, Giorgia [8 ]
Negri, Francesca V. [9 ]
Foschi, Francesco Giuseppe [10 ]
Valgiusti, Martina [1 ]
Ercolani, Giorgio [11 ,12 ]
Frassineti, Giovanni Luca [1 ]
机构：
[1] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol, Meldola, Italy
[2] IRST IRCCS, Unit Biostat & Clin Trials, Meldola, Italy
[3] Osped Gen Prov Macerata ASUR Marche AV3, Dept Med Oncol, Macerata, Italy
[4] Univ Hosp Cagliari, Dept Med Oncol, Cagliari, Italy
[5] Canc Inst Giovanni Paolo II, Med Oncol Unit, Bari, Italy
[6] Univ Campus Biomed, Dept Med Oncol, Via Alvaro del Portillo, Rome, Italy
[7] D Cotugno Hosp, Infect Dis & Intervent Ultrasound Unit, Naples, Italy
[8] IRST IRCCS, Biosci Lab, Meldola, Italy
[9] Univ Hosp, Med Oncol Unit, Parma, Italy
[10] AUSL Romagna, Faenza Hosp, DPT Internal Med, Forli, Italy
[11] AUSL Romagna, Morgagni Pierantoni Hospiatal, Dept Gen Surg, Forli, Italy
[12] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy
来源：
ONCOTARGET | 2016年 / 7卷 / 41期
关键词：
systemic immune-inflammation index; inflammation; biomarker; hepatocellular carcinoma; neutrophil-to-lymphocyte ratio; TO-LYMPHOCYTE RATIO; CIRCULATING TUMOR-CELLS; PROGNOSTIC-FACTOR;
D O I：
10.18632/oncotarget.11565
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We evalueted a systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) with the aim to explored their prognostic value in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. 56 advanced HCC patients receiving sorafenib were available for our analysis. Lymphocyte, neutrophil and platelet were measured before beginning of treatment and after one month. Patient with SII >= 360 showed lower median PFS (2.6 vs. 3.9 months, P < 0.026) and OS (5.6 vs. 13.9 months, P = 0.027) with respect to patients with SII < 360. NLR >= 3 had a lower median PFS (2.6 vs. 3.3 months, P < 0.049) but not OS (5.6 vs. 13.9 months, P = 0.062) than those with NLR < 3. After adjusting for clinical covariates SII and NLR remained an independent prognostic factor for OS. The SII and NLR represent potential prognostic indicator in patients with advanced HCC treated with sorafenib.
引用
收藏
页码：67142 / 67149
页数：8
相关论文
共 27 条
[1]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[2]   CANCER Inflammation lights the way to metastasis [J].
Coffelt, Seth B. ;
de Visser, Karin E. .
NATURE, 2014, 507 (7490) :48-49
[3]   Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis [J].
Cools-Lartigue, Jonathan ;
Spicer, Jonathan ;
McDonald, Braedon ;
Gowing, Stephen ;
Chow, Simon ;
Giannias, Betty ;
Bourdeau, France ;
Kubes, Paul ;
Ferri, Lorenzo .
JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (08) :3446-3458
[4]   Inflammation and cancer [J].
Coussens, LM ;
Werb, Z .
NATURE, 2002, 420 (6917) :860-867
[5]   Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer [J].
De Giorgi, Ugo ;
Mego, Michal ;
Scarpi, Emanuela ;
Giuliano, Mario ;
Giordano, Antonio ;
Reuben, James M. ;
Valero, Vicente ;
Ueno, Naoto T. ;
Hortobagyi, Gabriel N. ;
Cristofanilli, Massimo .
CLINICAL BREAST CANCER, 2012, 12 (04) :264-269
[6]   Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New [J].
Faloppi, Luca ;
Bianconi, Maristella ;
Memeo, Riccardo ;
Gardini, Andrea Casadei ;
Giampieri, Riccardo ;
Bittoni, Alessandro ;
Andrikou, Kalliopi ;
Del Prete, Michela ;
Cascinu, Stefano ;
Scartozzi, Mario .
BIOMED RESEARCH INTERNATIONAL, 2016, 2016
[7]   The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management [J].
Faloppi, Luca ;
Scartozzi, Mario ;
Bianconi, Maristella ;
Baroni, Gianluca Svegliati ;
Toniutto, Pierluigi ;
Giampieri, Riccardo ;
Del Prete, Michela ;
De Minicis, Samuele ;
Bitetto, Davide ;
Loretelli, Cristian ;
D'Anzeo, Marco ;
Benedetti, Antonio ;
Cascinu, Stefano .
BMC CANCER, 2014, 14
[8]   Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options [J].
Faloppi, Luca ;
Scartozzi, Mario ;
Maccaroni, Elena ;
Paolo, Marzia Di Pietro ;
Berardi, Rossana ;
Del Prete, Michela ;
Cascinu, Stefano .
CANCER TREATMENT REVIEWS, 2011, 37 (03) :169-177
[9]   Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab [J].
Ferrucci, P. F. ;
Ascierto, P. A. ;
Pigozzo, J. ;
Del Vecchio, M. ;
Maio, M. ;
Cappellini, G. C. Antonini ;
Guidoboni, M. ;
Queirolo, P. ;
Savoia, P. ;
Mandala, M. ;
Simeone, E. ;
Valpione, S. ;
Altomonte, M. ;
Spagnolo, F. ;
Cocorocchio, E. ;
Gandini, S. ;
Giannarelli, D. ;
Martinoli, C. .
ANNALS OF ONCOLOGY, 2016, 27 (04) :732-738
[10]   Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients [J].
Ferrucci, P. F. ;
Gandini, S. ;
Battaglia, A. ;
Alfieri, S. ;
Di Giacomo, A. M. ;
Giannarelli, D. ;
Cappellini, G. C. Antonini ;
De Galitiis, F. ;
Marchetti, P. ;
Amato, G. ;
Lazzeri, A. ;
Pala, L. ;
Cocorocchio, E. ;
Martinoli, C. .
BRITISH JOURNAL OF CANCER, 2015, 112 (12) :1904-1910
123